Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2015-07-30 Director's Dealing
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 75.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including shares acquired and options lapsed. The content is focused on reporting personal share transactions by a director, which aligns with insider trading disclosures. The document length is 3503 characters, which is short and specific to director dealings. Therefore, this document fits the category of Director's Dealing (DIRS).
2015-07-30 English
Prposed Issue of Securities to Chief Executive Officer 2 pages 119.5KB
Capital/Financing Update Classification · 95% confidence The document is a formal announcement addressed to the Australian Securities Exchange regarding a proposed issue of securities (performance rights) to the Chief Executive Officer. It references compliance with Listing Rule 3.10.3 and details the terms of the securities to be issued, including vesting conditions and shareholder approval to be sought at the upcoming Annual General Meeting. The document explicitly states that the company will lodge the relevant Appendix 3B as required by the Listing Rules and mentions that further details will be included in the 2015 Statutory Annual Report to be filed later. The content focuses on the issuance of securities and the related shareholder approval process rather than presenting financial results or detailed report data. This fits the category of a Capital/Financing Update, as it concerns company fundraising and capital structure changes through the issuance of performance rights to an executive. The document length (6113 characters) and content do not indicate it is a full report or an announcement of a report publication, but rather a direct announcement of a capital issuance event.
2015-07-30 English
Becoming a substantial holder 6 pages 224.8KB
Regulatory Filings
2015-06-30 English
29-06-2015 - Appendix 3B - exercise of employee options 13 pages 138.2KB
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including the class of securities, number issued, exercise prices, and terms. It references ASX rules and compliance, and includes sections on quotation of securities and agreements related to the listing of these securities. The content is focused on announcing and providing details about a new share issue and application for quotation of additional securities, rather than being a financial report, earnings release, or management discussion. It is a regulatory announcement related to capital raising and securities issuance. Therefore, the document fits best under the category 'Capital/Financing Update' (CAP). The document length is substantial and contains detailed issuance information, supporting a high confidence in classification.
2015-06-28 English
Pharmaxis Share Trading Policy - updated June 2015 7 pages 94.8KB
Governance Information Classification · 95% confidence The document is titled 'Pharmaxis Ltd Share Trading Policy' and contains detailed rules and guidelines about insider trading, trading blackout periods, trading clearances, and compliance with securities laws. It discusses the responsibilities of directors, officers, and employees regarding trading the company's shares and the legal framework governing such trading. There is no indication that this document is a financial report, earnings release, or any form of regulatory filing announcing financial results or corporate actions. Instead, it is a corporate policy document related to insider trading and share trading compliance. This type of document does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is a governance-related policy document outlining internal rules and compliance practices. Therefore, the most appropriate classification is Governance Information (CGR). The document length (15,000 characters) and content confirm it is a full policy document, not a brief announcement or certification.
2015-06-18 English
Change in substantial holding 4 pages 178.5KB
Regulatory Filings
2015-06-17 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.